First UK patient enrolled in peanut allergy trial
pharma times | July 12, 2017
Children and adolescents in the UK with peanut allergy are among the first to enrol in a Europe-wide study investigating a new oral immunotherapy for the condition. The Phase III ARTEMIS trial is assessing the safety and effectiveness of Aimmune Therapeutics’ oral biologic AR101 in desensitising patients aged 4 to 17 years to peanut protein, in order to protect them from experiencing life-threatening reactions upon accidental exposure to peanut.